1.36 USD
▼-0.27-16.56%
盘后 1.57 +15.44%
2026-11-20
市值
$2.30M
市盈率
—
EPS
-14.93
股息率
—
52 周区间
1.35 – 37.50
成交量
20.36K
Beta
2.74
目标价
—
52W 低 1.3552W 高 37.50
价格走势
公司简介
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutic...